New imaging agent could help spot hidden tumors
NCT ID NCT01697930
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a new radioactive drug called [18F] Fluoroglutamine, which is designed to be used with PET scanners. Researchers want to see how long it stays in the blood and where it goes in the body, especially whether it collects in tumors. 67 adults with solid cancers or lymphoma will receive a small injection and then have PET scans. The goal is to gather safety and imaging data, not to treat the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F] 4-L-Fluoroglutamine (2S,4R) (a radioactive tracer for PET scans)
What this could lead to
If successful, this could lead to a new way to spot tumors using PET scans, potentially improving cancer detection.
What could go wrong
This is a very early Phase I study with only 67 people, focused on safety and imaging, not on treating cancer. It may not prove better than current scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States